Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/33723386/ below:

Effects of cancer screening restart strategies after COVID-19 disruption

Affiliations

• ¹ Department of Public Health, Erasmus MC, University Medical Center, Rotterdam, The Netherlands. l.kregting@erasmusmc.nl.
• ² Department of Public Health, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.

• PMID: 33723386
• PMCID: PMC7957464
• DOI: 10.1038/s41416-021-01261-9

Item in Clipboard

Lindy M Kregting et al. Br J Cancer. 2021 Apr.

• ¹ Department of Public Health, Erasmus MC, University Medical Center, Rotterdam, The Netherlands. l.kregting@erasmusmc.nl.
• ² Department of Public Health, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.

• PMID: 33723386
• PMCID: PMC7957464
• DOI: 10.1038/s41416-021-01261-9

Item in Clipboard

• Correction: Effects of cancer screening restart strategies after COVID-19 disruption.

  Kregting LM, Kaljouw S, de Jonge L, Jansen EEL, Peterse EFP, Heijnsdijk EAM, van Ravesteyn NT, Lansdorp-Vogelaar I, de Kok IMCM. Kregting LM, et al. Br J Cancer. 2021 Jul;125(1):145. doi: 10.1038/s41416-021-01427-5. Br J Cancer. 2021. PMID: 33976368 Free PMC article. No abstract available.

Background: Many breast, cervical, and colorectal cancer screening programmes were disrupted due to the COVID-19 pandemic. This study aimed to estimate the effects of five restart strategies after the disruption on required screening capacity and cancer burden.

Methods: Microsimulation models simulated five restart strategies for breast, cervical, and colorectal cancer screening. The models estimated required screening capacity, cancer incidence, and cancer-specific mortality after a disruption of 6 months. The restart strategies varied in whether screens were caught up or not and, if so, immediately or delayed, and whether the upper age limit was increased.

Results: The disruption in screening programmes without catch-up of missed screens led to an increase of 2.0, 0.3, and 2.5 cancer deaths per 100 000 individuals in 10 years in breast, cervical, and colorectal cancer, respectively. Immediately catching-up missed screens minimised the impact of the disruption but required a surge in screening capacity. Delaying screening, but still offering all screening rounds gave the best balance between required capacity, incidence, and mortality.

Conclusions: Strategies with the smallest loss in health effects were also the most burdensome for the screening organisations. Which strategy is preferred depends on the organisation and available capacity in a country.

PubMed Disclaimer

The authors declare no competing interests.

a Breast cancer, b Cervical cancer, c Colorectal cancer.

a Breast cancer, b Cervical cancer, c Colorectal cancer. The vertical dotted line represents the cut-off used in Fig. 3.

Cumulative excess in cancer-specific mortality…

Cumulative excess in cancer-specific mortality rate (per 100,000) after a 6-month disruption compared…

Cumulative excess in cancer-specific mortality rate (per 100,000) after a 6-month disruption compared to undisrupted screening over the years 2020–2030 for the different restart strategies.

• Impact of the COVID-19 pandemic on faecal immunochemical test-based colorectal cancer screening programmes in Australia, Canada, and the Netherlands: a comparative modelling study.

  de Jonge L, Worthington J, van Wifferen F, Iragorri N, Peterse EFP, Lew JB, Greuter MJE, Smith HA, Feletto E, Yong JHE, Canfell K, Coupé VMH, Lansdorp-Vogelaar I; COVID-19 and Cancer Global Modelling Consortium working group 2. de Jonge L, et al. Lancet Gastroenterol Hepatol. 2021 Apr;6(4):304-314. doi: 10.1016/S2468-1253(21)00003-0. Epub 2021 Feb 3. Lancet Gastroenterol Hepatol. 2021. PMID: 33548185 Free PMC article.

• [Oncological organized screening programmes in the COVID-19 era: an Italian survey on accrued delays, reboot velocity, and diagnostic delay estimates].

  Mantellini P, Battisti F, Armaroli P, Giubilato P, Ventura L, Zorzi M, Battagello J, Sassoli de Bianchi P, Senore C, Zappa M. Mantellini P, et al. Epidemiol Prev. 2020 Sep-Dec;44(5-6 Suppl 2):344-352. doi: 10.19191/EP20.5-6.S2.136. Epidemiol Prev. 2020. PMID: 33412828 Italian.

• Disparities in access to breast, colorectal, and cervical cancer screening programmes have intensified during the pandemic period. Findings of a health equity audit conducted by the Pavia Healthcare Protection Agency (Lombardy Region, Northern Italy).

  Girardi D, Vecchio R, Tanious M, Cacitti S, Ancarani C, Dalle Carbonare S, Perotti P, Bonafede C, Cavallo R, Gentile L, Parrini A, Lucente EM, Carlesso A, Cadum E, Cecconami L, Odone A, Deandrea S. Girardi D, et al. Epidemiol Prev. 2024 Mar-Apr;48(2):130-139. doi: 10.19191/EP24.2.A672.040. Epidemiol Prev. 2024. PMID: 38770730 English.

• Screening for cancer in low- and middle-income countries.

  Sankaranarayanan R. Sankaranarayanan R. Ann Glob Health. 2014 Sep-Oct;80(5):412-7. doi: 10.1016/j.aogh.2014.09.014. Ann Glob Health. 2014. PMID: 25512156 Review.

• A systematic review of special events to promote breast, cervical and colorectal cancer screening in the United States.

  Escoffery C, Rodgers KC, Kegler MC, Haardörfer R, Howard DH, Liang S, Pinsker E, Roland KB, Allen JD, Ory MG, Bastani R, Fernandez ME, Risendal BC, Byrd TL, Coronado GD. Escoffery C, et al. BMC Public Health. 2014 Mar 24;14:274. doi: 10.1186/1471-2458-14-274. BMC Public Health. 2014. PMID: 24661503 Free PMC article. Review.

• Impact of the COVID-19 pandemic on the breast cancer early diagnosis program in Brazil.

  Antonini M, Pinheiro DJPDC, Matos ABTMB, Ferraro O, Mattar A, Okumura LM, Lopes RGC, Real JM. Antonini M, et al. Prev Med Rep. 2023 Apr;32:102157. doi: 10.1016/j.pmedr.2023.102157. Epub 2023 Feb 20. Prev Med Rep. 2023. PMID: 36846466 Free PMC article.

• Assessment of the impact of the COVID-19 pandemic on health services use.

  Johnson KJ, Goss CW, Thompson JJ, Trolard AM, Maricque BB, Anwuri V, Cohen R, Donaldson K, Geng E. Johnson KJ, et al. Public Health Pract (Oxf). 2022 Jun;3:100254. doi: 10.1016/j.puhip.2022.100254. Epub 2022 Apr 5. Public Health Pract (Oxf). 2022. PMID: 35403073 Free PMC article.

• COVID-19 Vaccination and Cancer, the Need for more Data.

  Javadinia SA, Welsh JS, Mosavi Jarrahi A. Javadinia SA, et al. Asian Pac J Cancer Prev. 2021 Oct 1;22(10):3053-3054. doi: 10.31557/APJCP.2021.22.10.3053. Asian Pac J Cancer Prev. 2021. PMID: 34710978 Free PMC article. No abstract available.

• COVID-19 Pandemic Impact on Surgical Treatment Methods for Early-Stage Cervical Cancer: A Population-Based Study in Romania.

  Popescu A, Craina M, Pantea S, Pirvu C, Radu D, Marincu I, Bratosin F, Bogdan I, Hosin S, Citu C, Bernad E, Neamtu R, Dumitru C, Mocanu AG, Gluhovschi A. Popescu A, et al. Healthcare (Basel). 2022 Mar 28;10(4):639. doi: 10.3390/healthcare10040639. Healthcare (Basel). 2022. PMID: 35455816 Free PMC article.

• Impact of the COVID-19 pandemic on cervical cancer screening participation, abnormal cytology prevalence and screening interval in Catalonia.

  Robles C, Monfil L, Ibáñez R, Roura E, Font R, Peremiquel-Trillas P, Brotons M, Martínez-Bueno C, de Sanjosé S, Espinàs JA, Bruni L. Robles C, et al. Front Oncol. 2024 May 29;14:1338859. doi: 10.3389/fonc.2024.1338859. eCollection 2024. Front Oncol. 2024. PMID: 38873256 Free PMC article.

1. 1. Zielonke N, Gini A, Jansen EEL, Anttila A, Segnan N, Ponti A, et al. Evidence for reducing cancer-specific mortality due to screening for breast cancer in Europe: a systematic review. Eur. J. Cancer. 2020;127:191–206. doi: 10.1016/j.ejca.2019.12.010. - DOI - PubMed
2. 1. Jansen EEL, Zielonke N, Gini A, Anttila A, Segnan N, Vokó Z, et al. Effect of organised cervical cancer screening on cervical cancer mortality in Europe: a systematic review. Eur. J. Cancer. 2020;127:207–223. doi: 10.1016/j.ejca.2019.12.013. - DOI - PubMed
3. 1. Gini A, Jansen EEL, Zielonke N, Meester RGS, Senore C, Anttila A, et al. Impact of colorectal cancer screening on cancer-specific mortality in Europe: a systematic review. Eur. J. Cancer. 2020;127:224–235. doi: 10.1016/j.ejca.2019.12.014. - DOI - PubMed
4. 1. Richards M, Anderson M, Carter P, Ebert BL, Mossialos E. The impact of the COVID-19 pandemic on cancer care. Nat. Cancer. 2020;1:565–567. doi: 10.1038/s43018-020-0074-y. - DOI - PMC - PubMed
5. 1. Dinmohamed AG, Visser O, Verhoeven RHA, Louwman MWJ, van Nederveen FH, Willems SM, et al. Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands. Lancet Oncol. 2020;21:750–751. doi: 10.1016/S1470-2045(20)30265-5. - DOI - PMC - PubMed

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3